Community-Acquired Pneumonia (CAP)

Educational ExhibitTM: Driving Awareness of a Critical Issue

Cempra was developing a new drug to address a critical clinical issue, the increasing impact of resistance related to cases of Community-Acquired Pneumonia (CAP). With resistance rates being over 50% in many part of the world, the Educational ExhibitTM was employed to present current data and circumstances to a range of clinician audiences. Through a series of seven events, over 2,000 medical professionals toured the exhibit and viewed the latest data on CAP.